Analysis of a Welsh program offering live-attenuated shingles vaccines to people born after a certain date showed a 20 percent relative drop in dementia risk.

The inoculation, produced by the Butantan Institute in partnership with Austrian Valneva, had its registration approved this ...

Experts underscore the importance of MMR vaccinations to prevent the spread of measles and bolster collective immunity.

The shingles vaccine, typically administered to fend off a painful rash, might pack an unexpected benefit by delaying or even ...

Receiving the live-attenuated zoster vaccine (Zostavax ... In 2024, a study of 200,000 U.S. older adults showed the recombinant subunit zoster vaccine (Shingrix) was associated with a larger reduction ...

The strongest set of evidence to date indicates that people who had a shingles vaccine had significantly lower odds of developing dementia later in life.

Study in older adults found that individuals who received the shingles vaccine were 20% less likely to develop dementia than those who were unvaccinated.

A recent study found that people who received Zostavax, a older shingles vaccine, had a lower risk of developing dementia.

The interest in using recombinant bacteria as vaccine vectors for active immunotherapy ... This review will focus on the development of live-attenuated and killed strains of the intracellular ...

An important aspect of the study is that it was conducted with a live attenuated virus vaccine, withdrawn from the market in 2022. The adjuvanted recombinant vaccine available in Spain ...

Recent estimates suggest that about 7.4% of adults over 60 or 88 lakh people are living with dementia in India.